This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent. Top assignee: Hanmi Pharm. Co., Ltd.. Active years: 2023-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2025
Title: Innovations by Cho Rong Park
Introduction
Cho Rong Park is a notable inventor based in Hwaseong-si, South Korea. He has made significant contributions to the field of immunology through his innovative work on interleukin-2 analogs. With a total of 2 patents, his research focuses on enhancing the efficacy of immune responses.
Latest Patents
Cho Rong Park's latest patents include groundbreaking modifications to interleukin-2 alpha receptors. These patents disclose interleukin-2 analogs that exhibit increased binding affinity for interleukin-2 beta receptors. His work on immunostimulating IL-2 analogs represents a significant advancement in the field, as it relates to changes in interleukin-2 alpha receptors and the development of more effective therapeutic agents.
Career Highlights
Currently, Cho Rong Park is associated with Hanmi Pharmaceutical Co., Ltd., where he continues to push the boundaries of immunological research. His work has the potential to lead to new treatments for various diseases, showcasing his commitment to advancing medical science.
Collaborations
Throughout his career, Cho Rong Park has collaborated with esteemed colleagues, including Euh Lim Oh and Sang Yun Kim. These partnerships have fostered a collaborative environment that enhances the innovation process.
Conclusion
Cho Rong Park's contributions to immunology through his patents and collaborations highlight his role as a leading inventor in the field. His work promises to pave the way for future advancements in therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile